Erasca, Inc. (ERAS)

Market Cap	3.85B +621.3%
Revenue (ttm)	n/a
Net Income	-127.69M
EPS	-0.45
Shares Out	309.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,544,867
Open	12.03
Previous Close	12.00
Day's Range	11.88 - 12.48
52-Week Range	1.01 - 12.69
Beta	1.22
Analysts	Strong Buy
Price Target	5.78 (-53.57%)
Earnings Date	Mar 19, 2026

About ERAS

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: ERAS
• Website: https://www.erasca.com

Analyst Summary

According to 9 analysts, the average rating for ERAS stock is "Strong Buy." The 12-month stock price target is $5.78, which is a decrease of -53.57% from the latest price.

Price Target

$5.78

(-53.57% downside)

Analyst Consensus: Strong Buy